Adding Tislelizumab to Chemo Slows Advanced Nasopharyngeal Cancer

FRIDAY, April 22, 2022 -- The addition of tislelizumab to chemotherapy improves progression-free survival (PFS) in recurrent/metastatic nasopharyngeal cancer (RM NPC), according to a study presented April 18 as part of the American Society for...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news